WO2010095879A3 - 세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물 - Google Patents

세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물 Download PDF

Info

Publication number
WO2010095879A3
WO2010095879A3 PCT/KR2010/001031 KR2010001031W WO2010095879A3 WO 2010095879 A3 WO2010095879 A3 WO 2010095879A3 KR 2010001031 W KR2010001031 W KR 2010001031W WO 2010095879 A3 WO2010095879 A3 WO 2010095879A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
compositions
apoptosis
bound
genes
Prior art date
Application number
PCT/KR2010/001031
Other languages
English (en)
French (fr)
Other versions
WO2010095879A2 (ko
Inventor
한보람
김성열
박한오
Original Assignee
(주)바이오니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)바이오니아 filed Critical (주)바이오니아
Publication of WO2010095879A2 publication Critical patent/WO2010095879A2/ko
Publication of WO2010095879A3 publication Critical patent/WO2010095879A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 세포사멸 관련 유전자의 전사체에 결합하는 siRNA 및 이를 이용한 암 치료용 조성물에 관한 것으로, 보다 상세하게는 TRAF7(tumor necrosis factor receptor associated factor) 또는 TAB2(TAK1 binding protein 2) 유전자의 mRNA에 결합하여 상기 유전자의 발현을 억제함으로써, 암 세포 특이적으로 세포사멸에 이르게 하는 siRNA 및 상기 siRNA를 유효성분으로 하는 암 치료용 조성물에 관한 것이다. 본 발명의 siRNA 및 이를 포함하는 조성물은 암 세포 특이적으로 세포사멸을 일으키므로 항암치료시 정상세포를 손상시키지 않는 효과적인 치료제로 사용될 수 있다.
PCT/KR2010/001031 2009-02-20 2010-02-19 세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물 WO2010095879A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090014369A KR20100095206A (ko) 2009-02-20 2009-02-20 세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물
KR10-2009-0014369 2009-02-20

Publications (2)

Publication Number Publication Date
WO2010095879A2 WO2010095879A2 (ko) 2010-08-26
WO2010095879A3 true WO2010095879A3 (ko) 2011-02-24

Family

ID=42634338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001031 WO2010095879A2 (ko) 2009-02-20 2010-02-19 세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물

Country Status (2)

Country Link
KR (1) KR20100095206A (ko)
WO (1) WO2010095879A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940992B (zh) * 2022-05-26 2023-08-29 华南农业大学 lncRNA TAB2-AS调控TAB2在猪卵巢颗粒细胞中的应用
CN114941010B (zh) * 2022-05-26 2023-08-15 华南农业大学 Tab2在猪卵巢颗粒细胞中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095246A1 (en) * 2003-10-24 2005-05-05 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
US20080248024A1 (en) * 2007-02-28 2008-10-09 Korea Research Institute Of Bioscience And Biotechnology Therapeutic agent for cancer, inflammation, and auto-immune disease containing inhibitor of zinc finger protein 91

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095246A1 (en) * 2003-10-24 2005-05-05 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
US20080248024A1 (en) * 2007-02-28 2008-10-09 Korea Research Institute Of Bioscience And Biotechnology Therapeutic agent for cancer, inflammation, and auto-immune disease containing inhibitor of zinc finger protein 91

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 10 February 2008 (2008-02-10), "Homo sapiens TNF receptor-associated factor 7 (TRAF7), mRNA", Database accession no. NM 032271 *
DATABASE GENBANK 28 September 2008 (2008-09-28), "Homo sapiens TGF-beta activated kinase 1/ MAP3K7 binding protein 2 (TAB2), mRNA", Database accession no. NM 015093 *
HIROKI YOSHIDA ET AL.: "The Tumor Suppressor Cylindromatosis (CYLD) Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross- talk with TRAF6 and TRAF7.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 49, 2005, pages 41111 - 41121 *
LIANG-GUO XU ET AL.: "TRAF7 Potentiates MEKK3-induced AP 1 and CHOP Activation and Induces Apoptosis.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 17, 2004, pages 17278 - 17282 *
TEWIS BOUWMEESTER ET AL.: "A physical and functional map of the human TNF - /NF-K B signal transduction pathway.", NATURE CELL BIOLOGY., vol. 6, no. 2, 2004, pages 97 - 105 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
KR20100095206A (ko) 2010-08-30
WO2010095879A2 (ko) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
PH12018501827A1 (en) Cancer treatment
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
MX2009001309A (es) Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1.
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2009013077A (es) Derivados dde benzoxazolona.
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
EA201290822A1 (ru) Триазолоны в качестве ингибиторов синтазы жирных кислот
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
MY179042A (en) Kinase inhibitors with improved cyp safety profile
WO2009070244A3 (en) Methods for inhibiting fascin
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2012012518A3 (en) Inhibition of nonsense mediated decay pathways
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
WO2011047770A3 (de) Pyrazolopyrimidinderivate
WO2012037299A3 (en) Fatty acid synthase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10743954

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10743954

Country of ref document: EP

Kind code of ref document: A2